SCNXAnother lap around the compliance track
Scienture Holdings just bought itself some time. Nasdaq granted the pharma company a 180-day extension to meet the exchange’s $1 minimum bid price rule, pushing the deadline out to October 12, 2026.
Why you should care
This isn’t an immediate delisting drama. Shares of SCNX can keep trading on the Nasdaq Capital Market while the company works on getting the stock price back in line.
The fine print that matters
Nasdaq said Scienture was still okay on the other listing standards — things like market value of publicly held shares and the rest of the usual box-checking circus — so the bid-price issue is the only thing hanging over it right now.
For investors, that means the story is less "red alert" and more "please keep your eye on the tape." If the stock can’t regain compliance by the new deadline, then the next chapter gets a lot less cute.
Big picture: Scienture has time, not a victory lap. The company still needs the market to cooperate, and that’s usually the trickiest part of the plan.